Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Low Dose Carbon Monoxide Is Neuroprotective in Models of Parkinson's Disease
Movement Disorders
S42 - Movement Disorders: Genetics and Risk Modifiers (4:54 PM-5:06 PM)
008

Despite the many risks of smoking tobacco, the risk of PD is markedly reduced among smokers and may derive from biological activity of specific tobacco smoke constituent(s). On the basis of accumulating evidence supporting the therapeutic potential of CO in other disease contexts, this study set out to determine whether low dose CO is neuroprotective in PD models.

To evaluate the neuroprotective potential of low dose CO treatment in Parkinson disease (PD) models.

In an AAV-alpha-synuclein (aSyn) model, rats underwent right nigral injection of AAV1/2- asynA53T and left injection of empty AAV, followed by treatment with oral CO drug product (HBI-002 10ml/kg, daily by gavage) or vehicle. In a short-term MPTP model (40mg/kg, i.p.), mice were treated with inhaled CO (iCO) (250ppm) or air. In an in vitro rotenone model, SH-SY5Y cells exposed to rotenone were treated with CO (200 ppm) or air. All analyses, including immunohistochemistry for nigral aSyn and tyrosine hydroxylase, HPLC measurement of striatal dopamine, stereological cell counting, and biochemical analyses were conducted blinded to treatment condition.

Each HBI-002 treatment increased carboxy-hemoglobin to 6%. In the aSyn model, treatment with HBI-002 reduced ipsilateral loss of both striatal dopamine and TH-positive neurons in the substantia nigra pars compacta, and HBI-002 reduced aSyn aggregates and aSyn S129 phosphorylation. In the MPTP model, treatment with low dose iCO also reduced loss of striatal dopamine and loss of TH+ neurons. In saline-treated mice, iCO had no effect on striatal dopamine or TH+ cell counts. HBI-002 upregulated heme oxygenase-1, HIF-1a, and cathepsin D. In the rotenone model, treatment with low dose CO reduced cell death.

These results demonstrating reduced cell death and aSyn pathology in animal and cell models support the therapeutic potential of low dose CO for PD.
Authors/Disclosures
Stephen Neil Gomperts, MD, PhD (Massachusetts General Hospital)
PRESENTER
Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EIP. Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cowen. Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bob's Last Stand. Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Focus Boston. Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Expert connect. Dr. Gomperts has received personal compensation in the range of $0-$499 for serving as a Consultant for Mosaic. Dr. Gomperts has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jannsen. The institution of Dr. Gomperts has received research support from NIH. The institution of Dr. Gomperts has received research support from LBDA. The institution of Dr. Gomperts has received research support from DOD/CDMRP. The institution of Dr. Gomperts has received research support from FFFPRI. The institution of Dr. Gomperts has received research support from NIH. The institution of Dr. Gomperts has received research support from MJFF. The institution of Dr. Gomperts has received research support from NIH. The institution of Dr. Gomperts has received research support from NIH. The institution of Dr. Gomperts has received research support from MJFF. The institution of Dr. Gomperts has received research support from NIH. The institution of Dr. Gomperts has received research support from NIH. Dr. Gomperts has received intellectual property interests from a discovery or technology relating to health care.
Kenneth Rose, PhD (Massachusetts General Hospital) Dr. Rose has nothing to disclose.
Musab Zorlu, MD Dr. Zorlu has nothing to disclose.
Xiaofan Xue, MD Dr. Xue has nothing to disclose.
Waijiao Cai, PhD Dr. Cai has received personal compensation for serving as an employee of Pfizer .
Sonia Lin Ms. Lin has nothing to disclose.
Han K. Lee, Other Mr. Lee has nothing to disclose.
Edward Gomperts, MD (Children's Hospital of Los Angeles) Dr. Gomperts has stock in Hillhurst Biopharmaceuticals inc. The institution of Dr. Gomperts has received research support from Hillhurst Biopharmaceuticals inc. Dr. Gomperts has received intellectual property interests from a discovery or technology relating to health care.
Michael Schwarzschild, MD, PhD (Massachusetts General Hospital) The institution of Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial Biotech (indirectly, as a service of the Parkinson Study Group service). The institution of Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen (indirectly, as a service of the Parkinson Study Group service). The institution of Dr. Schwarzschild has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB (indirectly, as a service of the Parkinson Study Group service). Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Dr. Schwarzschild has received research support from NIH. The institution of Dr. Schwarzschild has received research support from Parkinson's Foundation. The institution of Dr. Schwarzschild has received research support from Michael J Fox Foundation. The institution of Dr. Schwarzschild has received research support from Farmer Family Foundation. Dr. Schwarzschild has a non-compensated relationship as a Chair, Executive Committee with the Parkinson Study Group that is relevant to AAN interests or activities.
Xiqun Chen, MD,PhD (Massachusetts General Hospital) Dr. Chen has nothing to disclose.